<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03222765</url>
  </required_header>
  <id_info>
    <org_study_id>EU-FP7 279074</org_study_id>
    <nct_id>NCT03222765</nct_id>
  </id_info>
  <brief_title>Prevention of Microvascular Complications in Prediabetes e-PREDICE Study</brief_title>
  <acronym>ePREDICE</acronym>
  <official_title>Early Prevention of Diabetes Complications in People With Hyperglycaemia in Europe: e-PREDICE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evidem Consultores SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Evidem Consultores SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: A significant proportion of pre-diabetics, show macro and micro vascular&#xD;
      complications associated with hyperglycaemia. Although many trials have demonstrated the&#xD;
      efficacy of lifestyle and pharmaceutical interventions in diabetes prevention, no trial has&#xD;
      evaluated the extent to which mid- and long-term complications can be prevented by early&#xD;
      interventions on hyperglycaemia.&#xD;
&#xD;
      Aims: To assess the long-term effects on multiple complications of hyperglycaemia of early&#xD;
      intensive management of hyperglycaemia with linagliptin, metformin or their combination added&#xD;
      to lifestyle intervention (LSI) (diet and physical activity), compared with LSI alone in&#xD;
      adults with non-diabetic intermediate hyperglycaemia (IFG, IGT or both).&#xD;
&#xD;
      Study Design: Investigator initiated (non-commercial), long-term, multi-centre, randomised,&#xD;
      partially double blinded, placebo controlled, phase-IIIb clinical trial with prospective&#xD;
      blinded outcome evaluation. Participants will be randomised to four parallel arms: 1) LSI + 2&#xD;
      placebo tablets/day; 2) LSI + 2 Metformin tablets of 850 mg/day; 3) LSI + 1 Linagliptin&#xD;
      tablets of 5 mg/day and 1 placebo; 4) LSI + 2 tablets of a fixed-dose combination of&#xD;
      Linagliptin 2.5mg and Metformin 850 /day. Active intervention will last for at least 2 years.&#xD;
&#xD;
      Setting and population: Males and Females with pre-diabetes (IFG, IGT or both) aged 45 to 74&#xD;
      years selected from primary care screening programs in 14 clinical centres from 10 countries:&#xD;
      Australia, Austria, Bulgaria, Greece, Italy, Kuwait, Poland, Serbia, Spain and Turkey and .&#xD;
      (N=1000)&#xD;
&#xD;
      Main Outcomes: The primary endpoint is a combined continous variable: &quot;the microvascular&#xD;
      complication Ã­ndex&quot; (MCI) composed by a linear combination of the Early Treatment Diabetic&#xD;
      Retinopathy Study Scale (ETDRS) score (based on retinograms), the level of urinary albumin to&#xD;
      creatinine ratio, and a measure of distal small fibre neuropathy (sudomotor test by&#xD;
      SUDOSCAN), measured during baseline visit and at 24th and 48th month visits after&#xD;
      randomisation. In addition, serological biomarkers of inflammation, vascular damage,&#xD;
      non-alcoholic fatty liver disease, insulin secretion, measures of quality of life, sleep&#xD;
      quality, neuropsychological evaluation and endothelial function will be also evaluated in a&#xD;
      subset of participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 15, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, parallel , single-blind, placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Two groups (linagliptin vs placebo) double-blind Two groups (metformin &amp; metformin+linagliptin) single-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Microvascular Complication Index &quot;MIC&quot; :</measure>
    <time_frame>2-year</time_frame>
    <description>linear combination of three continous variables: ETRSD score, UACR and sudomotor index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diabetic Retinopathy: Scale ETDRS</measure>
    <time_frame>2-year</time_frame>
    <description>ETDRS Score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine albumin to creatinine ratio (UACR)</measure>
    <time_frame>2-year</time_frame>
    <description>Ratio albumin to creatinine in mg/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sudomotor Index</measure>
    <time_frame>2-year</time_frame>
    <description>SUDOSCAN sweat function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of diabetes</measure>
    <time_frame>2-year</time_frame>
    <description>new cases of Type 2 Diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial dysfunction</measure>
    <time_frame>2-year</time_frame>
    <description>ENDOPATH measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>2-year</time_frame>
    <description>Insulin secretion and beta-cell function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation biomarkers</measure>
    <time_frame>2-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NAFLD biomarkers</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2-year</time_frame>
    <description>D15 questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive function</measure>
    <time_frame>2-year</time_frame>
    <description>MMSE questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>depressive symptoms</measure>
    <time_frame>2-year</time_frame>
    <description>WHO-MINI questionnaire</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo&#xD;
Lifestyle modification (diet and physical activity recommendations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin&#xD;
Lifestyle modification (diet and physical activity recommendations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin&#xD;
Lifestyle modification (diet and physical activity recommendations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin and Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination of Linagliptin and metformin&#xD;
Lifestyle modification (diet and physical activity recommendations)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, metformin, linagliptin, linagliptin + metformin</intervention_name>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_label>Linagliptin and Metformin</arm_group_label>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Impaired Fasting Glucose (IFG): Fasting Plasma Glucose (FPG) 6.1 to 6.9mmol/l and&#xD;
             2-hour Plasma Glucose (2-h PG): &lt;7.8mmol/L;&#xD;
&#xD;
          -  Impaired Glucose Tolerance (IGT): FPG &lt;7.0mmol/L and 2h PG &gt;_7.8 and &lt;11.1 mmol/L&#xD;
             -Informed consent given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes (T1D)&#xD;
&#xD;
          -  known or screen-detected Type 2 diabetes (T2D).&#xD;
&#xD;
          -  Use of any anti-diabetic drug within the 3 months prior to inclusion.&#xD;
&#xD;
          -  Previous cardiovascular event, stroke or revascularization procedure of any arterial&#xD;
             territory&#xD;
&#xD;
          -  Morbid obesity (BMI&gt;45)&#xD;
&#xD;
          -  Current renal replacement therapy.&#xD;
&#xD;
          -  Renal function impairment: GFR &lt;60 ml/min/1.73m2.&#xD;
&#xD;
          -  Previous diagnosis of liver cirrhosis or chronic hepatitis&#xD;
&#xD;
          -  Elevation of liver enzymes (AST/AST) &gt;3 times of the upper normal ranges** (6m or BL).&#xD;
&#xD;
          -  Previous diagnosis of acute or chronic pancreatitis&#xD;
&#xD;
          -  Elevation of pancreatic enzymes (Amylase/Lipase) &gt;3 times of the upper normal ranges&#xD;
             (6m or BL).&#xD;
&#xD;
          -  Previous diagnosis of Chronic Heart Failure (NYHA class III or higher).&#xD;
&#xD;
          -  Organ transplant or waiting for organ transplant.&#xD;
&#xD;
          -  Diagnosis of malignant neoplasm requiring chemotherapy, surgery, radiation or&#xD;
             palliative therapy in the previous 5 years.&#xD;
&#xD;
          -  End-stage or metastatic cancer.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to trial products or related products.&#xD;
&#xD;
          -  Known use of non prescribed narcotics or illicit drugs.&#xD;
&#xD;
          -  Simultaneous participation in any other clinical trial of an investigational agent.&#xD;
&#xD;
          -  Females of childbearing potential who are pregnant, breast-feeding or intend to become&#xD;
             pregnant.&#xD;
&#xD;
          -  Cataract that impedes the retinal evaluation of both eyes.&#xD;
&#xD;
          -  Ocular surgery planned in the next 6 months&#xD;
&#xD;
          -  Concomitant intraocular treatment (retina or choroid).&#xD;
&#xD;
          -  Tropicamide allergy&#xD;
&#xD;
          -  Participants with screen retinogram not optimal for retinal assessment&#xD;
&#xD;
          -  Complete amputation of one/ both hands or one/both feet.&#xD;
&#xD;
          -  Dementia, mental disorder or evident cognitive impairment unable to give informed&#xD;
             consent.&#xD;
&#xD;
          -  Institutionalization (nursing/mental health home, hospital, prison, etc).&#xD;
&#xD;
          -  Suspected renal artery stenosis Recent gastrointestinal bleeding (within the last&#xD;
             year)&#xD;
&#xD;
          -  Any circumstance where ongoing medication might lead to potential adverse drug effect.&#xD;
&#xD;
          -  Any other acute condition or exacerbation of chronic condition that in the&#xD;
             investigator's opinion would interfere with the trial initiation or visit schedules or&#xD;
             procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Gabriel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evidem Consultores SL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jaakko Tuomilehto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evidem Consultores SL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nisa Boukichou, Ms</last_name>
    <phone>+34914025066</phone>
    <email>nisa@ceiis.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margarita Alonso, MS</last_name>
    <phone>+34914025066</phone>
    <email>mgalonso@ceiis.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Salud Jose Marva</name>
      <address>
        <city>Madrid</city>
        <zip>28030</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Sanchez, MD</last_name>
      <phone>+34629</phone>
    </contact>
    <contact_backup>
      <last_name>Ana M Santos</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2017</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prediabetes lifestyle drugs microvascular complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

